GeneWEAVE Sponsoring Satellite Symposium Featuring Dr. Lance Peterson at asm2015 in New Orleans on June 1
GeneWEAVE Exhibiting at asm2015, Booth 143, in New Orleans, May 31 - June 2, 2015
GeneWEAVE Presents Data at SHEA 2015 for Direct-from-Sample Detection of CRE Utilizing Smarticles™ Assay
GeneWEAVE Receives Two Awards from DxMA
MDROs threaten modern medicine’s progress by making common infections fatal and dramatically increasing the risk of complications for many medical procedures such as surgery, transplants and chemotherapy.
To solve this problem a global call has been issued to develop new diagnostics that detect MDROs and measure antibiotic effectiveness fast enough to make time-critical clinical decisions.
More than 2 million
people in the U.S. acquire a serious antibiotic-resistant bacterial infection every year and at least 23,000 people die as a result.1
1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. [Accessed 7/30/2014].
Click above to learn more.
GeneWEAVE’s Smarticles™ technology is a new class of molecular diagnostics that can quickly detect MDROs and assess antibiotic susceptibility directly from clinical samples.
For the first time, the speed and simplicity of molecular diagnostics is combined with the antibiotic susceptibility information that is critical for MDRO surveillance and choosing the right drug for the right bug.
GeneWEAVE is using Smarticles™ technology to develop elegantly simple Sample-In/Susceptibility-Out IVD Solutions.
The first system in development is the vivoDx™—a fully automated, random-access system designed to meet the needs of hospital labs facing the diagnostic challenge of MDRO detection and antibiotic therapy guidance.
Products are not cleared by FDA for sale in the US
GeneWEAVE and Smarticles are trademarks of GeneWEAVE Biosciences Inc.
© 2014. GeneWEAVE Biosciences Inc. All rights reserved. ML14002.03